Analyzing Johnson & Johnson's Bankruptcy Claim: Good Strategy or Bad Ethics?


Pharma giant Johnson & Johnson announced plans in November 2021 to split its pharmaceutical and medical devices divisions and its consumer products division into two publicly traded companies. The month prior, Johnson & Johnson also created a spin-off company which immediately filed for bankruptcy, a savvy but ethically dubious way of sidestepping the growing number of lawsuits against the company over its role in the opioid crisis and the alleged cancer-causing agents contained in its baby powder. This case covers J&J’s latest strategic maneuvers and asks students to discuss them through the lens of strategic management and ethics.

You are not authorized to view Teaching Notes. Please contact your librarian for access or sign in to your existing instructor profile.
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles